Pharmacog aims at identifying a research tool matrix capable of accelerating drug development in Alzheimer’s disease (AD) in order to better show clinical efficacy of disease-modifying drugs. Upon completion the project will generate tools to better define the therapeutic potential of each drug candidate, markers to select potential responders to these drugs and diagnostic markers to follow the drug’s efficacy with respect to disease progression allowing the gain better and faster insight in the clinical efficacy of drugs during clinical trials and speed approval of pertinent drugs in AD.
The unique know-how of ICDD in the discovery and validation of biomarkers using the patented Promembrane® technology® will participate in the success of the Pharmacog project studying the impact of the inflammatory processes and their regulation in AD progression. “AD is a key area of development for ICDD; we are committed to the development of more pertinent stratification markers identifying more accurately prodromal stages of the disease to enhance therapeutic interventions while it is still possible” says Nathalie Compagnone CEO of ICDD. Our participation in the program validates the interest of our technology in identifying markers essential to therapeutic developments that give scientists and clinicians a better understanding of when and how the pertinent therapeutic interventions can occur.